The degree of HLA matching determines the incidence of cytokine release syndrome and associated nonrelapse mortality in matched related and unrelated allogeneic stem cell transplantation with post-transplant cyclophosphamide

References

• Luznik L, O'Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641–650. doi:10.1016/j.bbmt.2008.03.005
   PubMed Web of Science ®Google Scholar
• Williams L, Cirrone F, Cole K, et al. Post-transplantation cyclophosphamide: from HLA-haploidentical to matched-related and matched-unrelated donor blood and marrow transplantation. Front Immunol. 2020;11:636. doi:10.3389/fimmu.2020.00636
   PubMed Web of Science ®Google Scholar
• Wachsmuth LP, Patterson MT, Eckhaus MA, et al. Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression. J Clin Invest. 2019;129(6):2357–2373. doi:10.1172/JCI124218
   PubMed Web of Science ®Google Scholar
• Nunes NS, Kanakry CG. Mechanisms of graft-versus-host disease prevention by post-transplantation cyclophosphamide: an evolving understanding. Front Immunol. 2019;10:2668. doi:10.3389/fimmu.2019.02668 eCollection 2019.
   PubMed Web of Science ®Google Scholar
• O'Donnell P, Raj K, Pagliuca A. High fever occurring 4 to 5 days post-transplant of haploidentical bone marrow or peripheral blood stem cells after reduced-intensity conditioning associated with the use of post-transplant cyclophosphamide as prophylaxis for graft-versus-host disease. Biol Blood Marrow Transplant. 2015;21(1):197–198. doi:10.1016/j.bbmt.2014.10.008
   PubMed Web of Science ®Google Scholar
• Abboud R, Keller J, Slade M, et al. Severe cytokine-release syndrome after T cell-replete peripheral blood haploidentical donor transplantation is associated with poor survival and anti-IL-6 therapy is safe and well tolerated. Biol Blood Marrow Transplant. 2016;22(10):1851–1860. doi:10.1016/j.bbmt.2016.06.010
   PubMed Web of Science ®Google Scholar
• Arango M, Combariza JF. Fever after peripheral blood stem cell infusion in haploidentical transplantation with post-transplant cyclophosphamide. Hematol Oncol Stem Cell Ther. 2017;10(2):79–84. doi:10.1016/j.hemonc.2017.03.001
   PubMedGoogle Scholar
• Raj RV, Hamadani M, Szabo A, et al. Peripheral blood grafts for T cell-replete haploidentical transplantation increase the incidence and severity of cytokine release syndrome. Biol Blood Marrow Transplant. 2018;24(8):1664–1670. doi:10.1016/j.bbmt.2018.04.010
   PubMed Web of Science ®Google Scholar
• McCurdy SR, Muth ST, Tsai HL, et al. Early fever after haploidentical bone marrow transplantation correlates with class II HLA-mismatching and myeloablation but not outcomes. Biol Blood Marrow Transplant. 2018;24(10):2056–2064. doi:10.1016/j.bbmt.2018.06.004
   PubMed Web of Science ®Google Scholar
• Sugita J, Kagaya Y, Miyamoto T, et al. Myeloablative and reduced-intensity conditioning in HLA-haploidentical peripheral blood stem cell transplantation using post-transplant cyclophosphamide. Bone Marrow Transplant. 2019;54(3):432–441. doi:10.1038/s41409-018-0279-1
   PubMed Web of Science ®Google Scholar
• Solh MM, Dickhaus E, Solomon SR, et al. Fevers post infusion of T cell replete HLA mismatched haploidentical hematopoietic stem cells with posttransplant cyclophosphamide: risk factors and impact on transplant outcomes. Bone Marrow Transplant. 2019;54(11):1756–1763. doi:10.1038/s41409-019-0522-4
   PubMed Web of Science ®Google Scholar
• Imus PH, Blackford AL, Bettinotti M, et al. Severe cytokine release syndrome after haploidentical peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2019;25(12):2431–2437. doi:10.1016/j.bbmt.2019.07.027
   PubMed Web of Science ®Google Scholar
• Mariotti J, Taurino D, Marino F, et al. Pretransplant active disease status and HLA class II mismatching are associated with increased incidence and severity of cytokine release syndrome after haploidentical transplantation with posttransplant cyclophosphamide. Cancer Med. 2020;9(1):52–61. doi:10.1002/cam4.2607
   PubMed Web of Science ®Google Scholar
• Abid MB, Hamadani M, Szabo A, et al. Severity of cytokine release syndrome and its association with infections after T cell-replete haploidentical related donor transplantation. Biol Blood Marrow Transplant. 2020;26(9):1670–1678. doi:10.1016/j.bbmt.2020.06.006
   PubMed Web of Science ®Google Scholar
• Modi D, Albanyan O, Kim S, et al. Grade 3-4 cytokine release syndrome is associated with poor survival in haploidentical peripheral blood stem cell transplantation. Leuk Lymphoma. 2021;62(8):1982–1989. doi:10.1080/10428194.2021.1891231
   PubMed Web of Science ®Google Scholar
• Jayakumar I, Uppuluri R, Lakshmanan C, et al. Risk-adapted therapy for the management of cytokine release syndrome in children undergoing unmanipulated haploidentical stem cell transplantation. Pediatr Transplant. 2021;25(5):e13964.
   PubMed Web of Science ®Google Scholar
• Kurita N, Sakamoto T, Kato T, et al. Early administration of cyclosporine may reduce the incidence of cytokine release syndrome after HLA-haploidentical hematopoietic stem-cell transplantation with post-transplant cyclophosphamide. Ann Hematol. 2021;100(5):1295–1301. doi:10.1007/s00277-021-04439-6
   PubMed Web of Science ®Google Scholar
• Cho C, Perales MA. Rapid identification of cytokine release syndrome after haploidentical PBSC transplantation and successful therapy with tocilizumab. Bone Marrow Transplant. 2016;51(12):1620–1621. doi:10.1038/bmt.2016.229
   PubMed Web of Science ®Google Scholar
• Abboud R, Wan F, Mariotti J, et al. Cytokine release syndrome after haploidentical hematopoietic cell transplantation: an international multicenter analysis. Bone Marrow Transplant. 2021;56(11):2763–2770. doi:10.1038/s41409-021-01403-w
   PubMed Web of Science ®Google Scholar
• Otoukesh S, Elmariah H, Yang D, et al. Cytokine release syndrome following peripheral blood stem cell haploidentical hematopoietic cell transplantation with post-transplantation cyclophosphamide. Transplant Cell Ther. 2022;28(2):111.e1-111–e8. doi:10.1016/j.jtct.2021.11.012
   Google Scholar
• Wang L, Dai B, Gao W, et al. Clinical significance of haplo-fever and cytokine profiling after graft infusion in allogeneic stem cell transplantation from haplo-identical donors. Front Med (Lausanne). 2022;9:820591. doi:10.3389/fmed.2022.820591
   PubMed Web of Science ®Google Scholar
• Solán L, Landete E, Bailén R, et al. Cytokine release syndrome after allogeneic stem cell transplantation with posttransplant cyclophosphamide. Hematol Oncol. 2020;38(4):597–603. doi:10.1002/hon.2772
   PubMed Web of Science ®Google Scholar
• Rappazzo KC, Zahurak M, Bettinotti M, et al. Nonmyeloablative, HLA-mismatched unrelated peripheral blood transplantation with high-dose post-transplantation cyclophosphamide. Transplant Cell Ther. 2021;27(11):909.e1-909–e6. doi:10.1016/j.jtct.2021.08.013
   Google Scholar
• Fernández-Viña MA, Klein JP, Haagenson M, et al. Multiple mismatches at the low expression HLA loci DP, DQ, and DRB3/4/5 associate with adverse outcomes in hematopoietic stem cell transplantation. Blood. 2013;121(22):4603–4610. doi:10.1182/blood-2013-02-481945
   PubMed Web of Science ®Google Scholar
• Fleischhauer K, Shaw BE, Gooley T, et al. Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study. Lancet Oncol. 2012;13(4):366–374. doi:10.1016/S1470-2045(12)70004-9
   PubMed Web of Science ®Google Scholar
• Soltermann Y, Heim D, Medinger M, et al. Reduced dose of post-transplantation cyclophosphamide compared to ATG for graft-versus-host disease prophylaxis in recipients of mismatched unrelated donor hematopoietic cell transplantation: a single-center study. Ann Hematol. 2019;98(6):1485–1493. doi:10.1007/s00277-019-03673-3
   PubMed Web of Science ®Google Scholar
• Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625–638. doi:10.1016/j.bbmt.2018.12.758
   PubMed Web of Science ®Google Scholar
• Common Terminology Criteria for Adverse Events (CTCAE) Version 5. Published: november 27. US department of health and human services, national institutes of health. National Cancer Institute.
   Google Scholar
• Przepiorka D, Weisdorf D, Martin P, et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1994;15(6):825–828. 1995
   Web of Science ®Google Scholar
• Jagasia MH, Greinix HT, Arora M, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: i. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant. 2015;21(3):389–401.e1. doi:10.1016/j.bbmt.2014.12.001
   PubMed Web of Science ®Google Scholar
• Armand P, Kim HT, Logan BR, et al. Validation and refinement of the disease risk index for allogeneic stem cell transplantation. Blood. 2014;123(23):3664–3671. doi:10.1182/blood-2014-01-552984
   PubMed Web of Science ®Google Scholar
• Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912–2919. doi:10.1182/blood-2005-05-2004
   PubMed Web of Science ®Google Scholar
• Gratwohl A. The EBMT risk score. Bone Marrow Transplant. 2012;47(6):749–756. doi:10.1038/bmt.2011.110
   PubMed Web of Science ®Google Scholar
• Ruggeri A, Labopin M, Ciceri F, et al. Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWPEBMT analysis on patients with AML in remission. Bone Marrow Transplant. 2016;51(4):610–611. doi:10.1038/bmt.2015.305
   PubMed Web of Science ®Google Scholar
• Iacobelli S, On behalf of the EBMT Statistical Committee. Suggestions on the use of statistical methodologies in studies of the european group for blood and marrow transplantation. Bone Marrow Transplant. 2013; Mar48 Suppl 1: s 1–37. doi:10.1038/bmt.2012.282
   Web of Science ®Google Scholar
• Dehn J, Spellman S, Hurley CK, et al. Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR. Blood. 2019;134(12):924–934. doi:10.1182/blood.2019001212
   PubMedGoogle Scholar
• Khimani F, Ranspach P, Elmariah H, et al. Increased infections and delayed CD4+ T cell but faster B cell immune reconstitution after post-transplantation cyclophosphamide compared to conventional GVHD prophylaxis in allogeneic transplantation. Transplant Cell Ther. 2021;27(11):940–948. doi:10.1016/j.jtct.2021.07.023
   PubMedGoogle Scholar
• Crivello P, Heinold A, Rebmann V, et al. Functional distance between recipient and donor HLA-DPB1 determines nonpermissive mismatches in unrelated HCT. Blood. 2016;128(1):120–129. doi:10.1182/blood-2015-12-686238
   PubMed Web of Science ®Google Scholar
• van Balen P, Kester MGD, de Klerk W, et al. Immunopeptidome analysis of HLA-DPB1 allelic variants reveals new functional hierarchies. J Immunol. 2020;204(12):3273–3282. doi:10.4049/jimmunol.2000192
   PubMed Web of Science ®Google Scholar
• Patel SS, Ahn KW, Khanal M, et al. Noninfectious pulmonary toxicity after allogeneic hematopoietic cell transplantation. Transplant Cell Ther. 2022;28(6):310–320. doi:10.1016/j.jtct.2022.03.015
   PubMedGoogle Scholar
• Balaguer-Rosello A, Bataller L, Piñana JL, et al. Noninfectious neurologic complications after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019;25(9):1818–1824. doi:10.1016/j.bbmt.2019.05.024
   PubMed Web of Science ®Google Scholar
• Gust J, Ponce R, Liles WC, et al. Cytokines in CAR T cell-associated neurotoxicity. Front Immunol. 2020; Dec 1611:577027. doi:10.3389/fimmu.2020.577027
   PubMed Web of Science ®Google Scholar
• Sugita J, Kamimura T, Ishikawa T, et al. Reduced dose of posttransplant cyclophosphamide in HLA-haploidentical peripheral blood stem cell transplantation. Bone Marrow Transplant. 2021;56(3):596–604. doi:10.1038/s41409-020-01065-0
   PubMed Web of Science ®Google Scholar
• Duléry R, Goudet C, Mannina D, et al. Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies. Bone Marrow Transplant. 2023;58(4):386–392. doi:10.1038/s41409-022-01908-y
   PubMed Web of Science ®Google Scholar